Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab
F. Poizeau, Emmanuel Nowak, Sandrine Kerbrat, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 11, pp. 1208-1208
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
Kevin Yang, Allen S. W. Oak, Boni E. Elewski
American Journal of Clinical Dermatology (2020) Vol. 22, Iss. 2, pp. 173-192
Open Access | Times Cited: 145
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
Jashin J. Wu, Arthur Kavanaugh, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 6, pp. 797-806
Open Access | Times Cited: 112
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
Pablo A. Olivera, Stéphane Zuily, Paulo Gustavo Kotze, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 12, pp. 857-873
Open Access | Times Cited: 104
Immune cell profiling in atherosclerosis: role in research and precision medicine
Dawn Fernandez, Chiara Giannarelli
Nature Reviews Cardiology (2021) Vol. 19, Iss. 1, pp. 43-58
Open Access | Times Cited: 91
Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*
Kenneth B. Gordon, Mark Lebwohl, Kim Papp, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 3, pp. 466-475
Open Access | Times Cited: 75
The metabolism-modulating activity of IL-17 signaling in health and disease
Rami Bechara, Mandy J. McGeachy, Sarah L. Gaffen
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 5
Open Access | Times Cited: 61
Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis
Shivani Mattay, Mohammad Zamani, Dany Saturno, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 5, pp. 961-970.e12
Closed Access | Times Cited: 23
Generalized pustular psoriasis: A nationwide population‐based study using the National Health Data System in France
M. Viguier, Malek Bentayeb, Jessica Azzi, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 6, pp. 1131-1139
Open Access | Times Cited: 11
Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients
Giovanni Paolino, Sandra Buratta, Santo Raffaele Mercuri, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 32
Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS)
Richard H. Woods
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 8, pp. 2386-2395
Closed Access | Times Cited: 32
Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study
Olivier Fakih, Maxime Desmarets, Bérenger Martin, et al.
Lara D. Veeken (2023) Vol. 62, Iss. 10, pp. 3317-3322
Closed Access | Times Cited: 18
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
Laura Pina Vegas, Philippe Le Corvoisier, Laëtitia Penso, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 4, pp. 1589-1599
Open Access | Times Cited: 39
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Ali Al‐Janabi, Z.Z.N. Yiu
Psoriasis Targets and Therapy (2022) Vol. Volume 12, pp. 1-14
Open Access | Times Cited: 26
The cardiometabolic conditions of psoriatic disease
Éric Toussirot, Irène Gallais-Sérézal, F. Aubin
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 24
The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
Aikaterini Tsiogka, Stamatios Gregoriou, Alexander Stratigos, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 318-318
Open Access | Times Cited: 16
Comorbidities in Psoriatic Arthritis: A Narrative Review
Alexandros Panagiotopoulos, G. Fragoulis
Clinical Therapeutics (2023) Vol. 45, Iss. 2, pp. 177-189
Closed Access | Times Cited: 14
Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review and meta‐analysis
Noémi Ágnes Galajda, Fanni Adél Meznerics, Péter Mátrai, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 6, pp. 1070-1088
Open Access | Times Cited: 6
Dysregulated haemostasis in thrombo-inflammatory disease
Paula Klavina, Gemma Leon, Annie M. Curtis, et al.
Clinical Science (2022) Vol. 136, Iss. 24, pp. 1809-1829
Open Access | Times Cited: 19
Biomarkers and biologics related with psoriasis and psoriatic arthritis
Weize Gao, Zhan Wang, Wenshuai Li, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110646-110646
Closed Access | Times Cited: 13
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Kim Papp, Richard B. Warren, Lawrence Green, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 9, pp. e542-e552
Closed Access | Times Cited: 13
Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm
F. Poizeau, Sophie Leducq, L. Fardet, et al.
Annales de Dermatologie et de Vénéréologie (2024) Vol. 151, Iss. 3, pp. 103287-103287
Open Access | Times Cited: 4
Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases
Maya H Buch, Ziad Mallat, Marc R. Dweck, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 614-634
Closed Access | Times Cited: 4
Cardiovascular Disease-Associated Skin Conditions
Lía Hojman, Claudio Karsulovic
Vascular Health and Risk Management (2022) Vol. Volume 18, pp. 43-53
Open Access | Times Cited: 19
Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
Hong Ki Min, Se Hee Kim, Hae‐Rim Kim, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13913-13913
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top